Literature DB >> 12968095

Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Leo R Brancazio, Amy P Murtha, R Phillps Heine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12968095     DOI： 10.1056/NEJM200309113491115

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 2.  Progestin treatment for the prevention of preterm birth.

Authors:  Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield
Journal:  Acta Obstet Gynecol Scand       Date:  2011-06-27       Impact factor: 3.636

3.  17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.

Authors:  David B Nelson; Donald D McIntire; Jeffrey McDonald; John Gard; Paula Turrichi; Kenneth J Leveno
Journal:  Am J Obstet Gynecol       Date:  2017-02-20       Impact factor: 8.661

4.  Terbutaline increases the cervical resistance of the pregnant rat in vitro.

Authors:  Róbert Gáspár; Zoltán Kolarovszki-Sipiczki; Eszter Ducza; Eszter Páldy; Sándor Benyhe; Anna Borsodi; George Falkay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-12       Impact factor: 3.000

5.  Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro.

Authors:  Donal J Sexton; Michael W O'Reilly; Anne M Friel; John J Morrison
Journal:  Reprod Biol Endocrinol       Date:  2004-12-07       Impact factor: 5.211

6.  Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors:  Helen Y How; Baha M Sibai
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.